PET with 18F-Fluorodeoxyglucose/Computed Tomography in the Management of Pediatric Sarcoma - 08/06/20

Résumé |
The role for PET with fludeoxyglucose F 18 (18F-FDG PET)/computed tomography (CT) in the management of pediatric sarcomas continues to be controversial. The literature supports a role for PET/CT in the staging and surveillance of certain specific pediatric sarcoma subtypes; however, the data are less clear regarding whether PET/CT can be used as a biomarker for prognostication. Despite the interest in using this imaging modality in the management of pediatric sarcomas, most studies are limited by retrospective design and small sample size. Additional data are necessary to fully understand how best to use 18F-FDG PET/CT in pediatric sarcoma management.
Le texte complet de cet article est disponible en PDF.Keywords : Osteosarcoma, Ewing sarcoma, Rhabdomyosarcoma, Non-rhabdomyosarcoma soft tissue sarcoma, 18 F-FDG PET/CT
Plan
Vol 15 - N° 3
P. 333-347 - juillet 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
